Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer.
Open Access Maced J Med Sci
; 7(24): 4244-4249, 2019 Dec 30.
Article
em En
| MEDLINE
| ID: mdl-32215071
ABSTRACT
BACKGROUND:
In recent times, scientists have found new treatments for colorectal cancer patients.AIM:
The study is to evaluate the efficacy and toxicity of triplet combination chemotherapy of 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) for patients with metastatic colorectal cancer in stage IV.METHODS:
Uncontrolled clinical trial carried on 39 stage IV colorectal cancer patients.RESULTS:
The overall response rate of the treatment was 79.4%. The average progression-free survival was 13.4 ± 9 months. The overall survival rate at 12th month and 24th month were 90% and 76%, respectively. The proportion of granulocytopenia was 48.9%, no grade 3 or 4. Side effect beyond hematology was most seen in hepatic toxicity with 52.5%, mainly at grade 1. Vomiting was 18.3%, all at grade 1. Other adverse event was very low at percentage.CONCLUSIONS:
The triplet combination FOLFOXIRI chemotherapy improves the outcome of patients with metastatic colorectal cancer regarding rate of response, overall survival rate and progression-free survival, and the level of toxicity was acceptable.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article